徳島大学 / 教育研究者総覧 --- 山本高成

検索:

研究活動

個人のホームページ

https://researchmap.jp/yamamoto.takaaki (researchmap)

専門分野

○	医療薬学 (Clinical Pharmacy)

研究テーマ

○	抗菌薬のtherapeutic drug monitoringに関する臨床研究

著書・論文

(著書・論文等の業績についてはhttps://researchmap.jp/yamamoto.takaaki (researchmap)でも御覧頂けます．)

学術論文(審査論文):

1.	Kei Kawada, Chiemi Sato, Tomoaki Ishida, Yui Nagao, Takaaki Yamamoto, Kohei Jobu, Yukihiro Hamada, Yuki Izawa-Ishizawa, Keisuke Ishizawa and Shinji Abe : Vitamin D Supplementation and Allergic Rhinitis: A Systematic Review and Meta-Analysis, Medicina, 61, 2, 2025. (要約) Background and Objectives: Vitamin D supplementation is effective for allergic rhinitis; however, its usefulness is unclear. We conducted a systematic review and meta-analysis to examine the conditions in which vitamin D supplementation was effective in allergic rhinitis management. Materials and Methods: Randomized controlled trials of vitamin D supplementation used for patients with allergic rhinitis were searched for across different databases. We extracted scores on patients' symptoms and the medication types used as the baseline treatments and performed a meta-analysis to evaluate the effect of vitamin D supplementation on allergic rhinitis symptoms. Meta-regression and subgroup analyses were performed for the average age, proportion of female participants, concomitant medications, vitamin D administration durations, and baseline serum 25-hydroxyvitamin D levels. Results: In total, 2389 articles were screened, and 5 randomized controlled trials (RCTs) were included in the meta-analysis. Compared with placebos, vitamin D supplementation alleviated allergic rhinitis symptoms, although the difference was not significant; there was significant heterogeneity among studies (standardized mean difference [SMD] = -2.69, 95% confidence interval [CI]: -6.20 to 0.82, I2 = 98%, p < 0.01). The proportion of female participants in the RCTs (slope: 0.21, p = 0.026) and concomitant corticosteroid use (slope: -9.16, p = 0.005) influenced the vitamin D response. Compared with the placebos, vitamin D supplementation without corticosteroids alleviated the allergic rhinitis symptoms (SMD = -0.56, 95% CI: -0.90 to -0.23). Combination treatment with corticosteroids also non-significantly alleviated symptoms. Additionally, the heterogeneity between studies was significant (SMD = -5.97, 95% CI: -13.55 to 1.16, I2 = 99%, p < 0.01). Conclusions: The study results suggest that vitamin D supplementation alleviates allergic rhinitis symptoms, although the effects differ according to the patient's sex and concomitant medications. (キーワード) 25-hydroxyvitamin D / allergic rhinitis / dietary supplements / vitamin D (出版サイトへのリンク) ● Publication site (DOI): 10.3390/medicina61020355 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40005471 ● Summary page in Scopus @ Elsevier: 2-s2.0-85218977591 (DOI: 10.3390/medicina61020355, PubMed: 40005471, Elsevier: Scopus)
2.	Takaaki Yamamoto, Kei Kawada, Chiemi Sato, Tatsuya Tai, Kazunori Yamaguchi, Kenta Sumiyoshi, Atsushi Tada, Naohiro Kurokawa, Takahiro Motoki, Hiroaki Tanaka, Shinji Kosaka and Shinji Abe : Optimal Blood Sampling Time for Area under the Concentration-Time Curve Estimation of Vancomycin by Assessing the Accuracy of Four Bayesian Software., Biological & Pharmaceutical Bulletin, 47, 12, 2021-2027, 2024. (要約) Effective blood sampling times, beyond trough and peak levels, have not been determined for estimating vancomycin's area under the concentration-time curve (AUC) using the Bayesian software. The aim of this study was to evaluate the accuracy of AUC estimation at different blood sampling times during the same dosing interval at steady state utilizing data from a prior phase I trial of vancomycin. Six healthy adult participants were sampled following intravenous administration of 1g vancomycin for 1.5h every 12h. The AUC was estimated using four software packages and four population pharmacokinetic models. Accuracy was assessed using bias (difference between the estimated and reference AUC) and imprecision (absolute percentage difference between the estimated and reference AUC). The accuracy varied with the sampling time. The optimal two-point sampling times were determined to be 2.5 and 5.5h post-injection using software packages for EasyTDM, Practical AUC-guided therapeutic drug monitoring (TDM), and Anti-MRSA Agents TDM Analysis Software (incorporating Rodvold, Yamamoto, and Yasuhara models). In these estimations, the mean bias (range, -1.7 to 9.5µg·h/mL) was unbiased and the mean imprecision (range, -3.0% to 5.0%) was precise. The optimal one-point sampling time was 5.5h post-injection for Anti-MRSA Agents TDM Analysis Software, which incorporated the Yamamoto and Yasuhara models. In conclusion, optimal blood sampling times may vary depending on the software and model used. Our findings suggest that identifying specific sampling times could improve the efficacy of TDM in clinical practice. (キーワード) Humans / Vancomycin / Bayes Theorem / Anti-Bacterial Agents / Adult / Area Under Curve / Software / Male / Drug Monitoring / Female / Young Adult / Blood Specimen Collection / Models, Biological (出版サイトへのリンク) ● Publication site (DOI): 10.1248/bpb.b24-00485 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39647905 ● Search Scopus @ Elsevier (PMID): 39647905 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b24-00485 (DOI: 10.1248/bpb.b24-00485, PubMed: 39647905)
3.	T Tai, Takaaki Yamamoto, K Yamaguchi, M Watanabe, H Tanaka, Y Muraki and S Kosaka : Evaluation of the meropenem dosage and administration schedule in patients with bacteremia initial therapy., Journal of Infection and Chemotherapy, 29, 8, 749-753, 2023. (要約) The standard meropenem (MEPM) regimen allowed by insurance in Japan is 0.5 g two or three times a day. Differences in dosages and administration schedules in Japan were evaluated. Patients with bacteremia for whom MEPM was used as the initial treatment at our institution between 2016 and 2021 were included. We retrospectively investigated patients classified into two groups: those treated according to severe infections (high-dose groupand others (low-dose group). After propensity score matching, we compared the probability of achieving free drug blood levels above the minimum inhibitory concentration (MIC) in 24 h (%fT > MIC) and outcomes. The probability of 100% fT > MIC was significantly higher in the high-dose group (96.4% vs 74.5%, odds ratio [OR] = 0.3, 95% confidence interval [CI] = 0.2-0.4, P = < 0.001). Regarding outcomes, the 30-day mortality rate was significantly lower in the high-dose group (1.4% vs. 11.4%, OR = 8.0, 95% CI = 1.5-43.7, P = 0.019). To improve outcomes in patients with bacteremia treated with MEPM, support for appropriate antimicrobial use is necessary for compliance with the dosage and administration schedule according to severe infections in initial treatment. (キーワード) Humans / Meropenem / Anti-Bacterial Agents / Retrospective Studies / Anti-Infective Agents / Bacteremia / Microbial Sensitivity Tests / Thienamycins (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.jiac.2023.04.004 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37086895 ● Search Scopus @ Elsevier (PMID): 37086895 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jiac.2023.04.004 (DOI: 10.1016/j.jiac.2023.04.004, PubMed: 37086895)

国内講演発表:

1.	内藤芽衣, 吉田碧人, 武久京楓, 竹倉秀太, 山本高成, 川田敬, 佐藤智恵美, 金子美華, 加藤幸成, 西岡安彦, 阿部真治 : 抗 podoplanin 抗体 chLpMab-2 のコアフコース除去による C1q 結合性の検討, 第63 回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2024年11月.
2.	竹倉秀太, 吉田碧人, 武久京楓, 内藤芽衣, 山本高成, 川田敬, 佐藤智恵美, 金子美華, 加藤幸成, 西岡安彦, 阿部真治 : 抗podoplanin抗体によるADCC活性誘導に対する補体タンパク質C1qの影響について, 第63 回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2024年11月.
3.	武久京楓, 吉田碧人, 内藤芽衣, 竹倉秀太, 山本高成, 川田敬, 佐藤智恵美, 金子美華, 加藤幸成, 西岡安彦, 阿部真治 : がん特異的抗 podoplanin 抗体 humLpMab-23f の in vivo における検討, 第63 回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2024年11月.
4.	永尾優衣, 佐藤智恵美, 山川亜弓, 山本高成, 川田敬, 阿部真治 : アレルギー性鼻炎患者に対するビタミンDサプリメントの有用性―システマティックレビューとメタ解析, 第63回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(岡山), 2024年11月.
5.	川田敬, 山本高成, 佐藤智恵美, 小川敦, 相澤風花, 八木健太, 石澤有紀, 新村貴博, 阿部真治, 合田光寛, 石澤啓介 : 国立大学での学部教育の実情と学生のキャリアアップ支援, 第34回日本医療薬学年会, 2024年11月.
6.	山本高成, 川田敬, 佐藤智恵美, 田井達也, 山口佳津騎, 住吉健太, 多田篤史, 黒川直弘, 元木貴大, 田中裕章, 小坂信二, 阿部真治 : バンコマイシンの血中濃度-時間曲線下面積の推定のための最適な採血時間:4つのベイジアンソフトウェアの精度検証, 第34回日本医療薬学年会, 2024年11月.
7.	永尾優衣, 佐藤智恵美, 山川亜弓, 山本高成, 川田敬, 阿部真治 : ビタミンDサプリメントがアレルギー性鼻炎に与える効果の検討―システマティックレビューとメタ解析―, 日本薬学会第144年会(横浜), 2024年3月.
8.	南和日子, 佐藤智恵美, 山本高成, 川田敬, 阿部真治 : 電子版お薬手帳の利用推進における問題点の検討―徳島県の薬局薬剤師に対するアンケート調査より―, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2023年10月.
9.	山口千早紀, 佐藤智恵美, 永尾優衣, 山本高成, 川田敬, 阿部真治 : ベンゾジアゼピン受容体作動薬の服用と認知機能低下の関連性評価 ―システマティックレビューとメタ解析―, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2023年10月.
10.	和田拓也, 板倉智史, 吉田碧人, 山本高成, 川田敬, 佐藤智恵美, 金子美華, 加藤幸成, 西岡安彦, 阿部真治 : がん特異的抗podoplanin抗体chLpMab-23fのMPM胸腔内移植マウスモデルにおける抗腫瘍効果の検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), 2023年10月.
11.	板倉智史, 和田拓也, 吉田碧人, 山本高成, 川田敬, 佐藤智恵美, 金子美華, 加藤幸成, 西岡安彦, 阿部真治 : がん特異的抗podoplanin抗体chLpMab-2及びコアフコース除去抗体chLpMab-2fのin vivoにおける抗腫瘍効果の検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), 2023年10月.
12.	吉田碧人, 板倉智史, 和田拓也, 山本高成, 川田敬, 佐藤智恵美, 金子美華, 加藤幸成, 西岡安彦, 阿部真治 : がん特異的抗podoplanin抗体のコアフコース除去に伴うADCC増強とNK細胞活性化に関する検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), 2023年10月.